Stock price blurs the picture with this one. For various reason but mainly related to for losing exclusivity to generic drugs, Abbvie. I however believe that decline in stock price is unjustified at this magnitude. This is the earnings growth picture.
Now let’s overlay stock price over it with FastGraphs.
P/E 8.2, is quite low as EPS growth estimates still are positive. Lowe but positive. The orange live marks P/E 15 which is considered fair value for most stocks.